SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Mascalzoni Deborah 1973 ) "

Sökning: WFRF:(Mascalzoni Deborah 1973 )

  • Resultat 1-10 av 55
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Pal, Gian, et al. (författare)
  • Genetic Testing in Parkinson's Disease.
  • 2023
  • Ingår i: Movement Disorders. - 0885-3185 .- 1531-8257. ; 38:8, s. 1384-1396
  • Tidskriftsartikel (refereegranskat)abstract
    • Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct-to-consumer settings. Although the potential utility of clinical testing is expanding, there are currently no proven gene-targeted therapies, but clinical trials are underway. Furthermore, genetic testing practices vary widely, as do knowledge and attitudes of relevant stakeholders. The specter of testing mandates financial, ethical, and physician engagement, and there is a need for guidelines to help navigate the myriad of challenges. However, to develop guidelines, gaps and controversies need to be clearly identified and analyzed. To this end, we first reviewed recent literature and subsequently identified gaps and controversies, some of which were partially addressed in the literature, but many of which are not well delineated or researched. Key gaps and controversies include: (1) Is genetic testing appropriate in symptomatic and asymptomatic individuals without medical actionability? (2) How, if at all, should testing vary based on ethnicity? (3) What are the long-term outcomes of consumer- and research-based genetic testing in presymptomatic PD? (4) What resources are needed for clinical genetic testing, and how is this impacted by models of care and cost-benefit considerations? Addressing these issues will help facilitate the development of consensus and guidelines regarding the approach and access to genetic testing and counseling. This is also needed to guide a multidisciplinary approach that accounts for cultural, geographic, and socioeconomic factors in developing testing guidelines. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
  •  
2.
  • Saunders-Pullman, Rachel, et al. (författare)
  • International Genetic Testing and Counseling Practices for Parkinson's Disease.
  • 2023
  • Ingår i: Movement Disorders. - 0885-3185 .- 1531-8257. ; 38:8, s. 1527-1535
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: There is growing clinical and research utilization of genetic testing in Parkinson's disease (PD), including direct-to-consumer testing.OBJECTIVES: The aim is to determine the international landscape of genetic testing in PD to inform future worldwide recommendations.METHODS: A web-based survey assessing current practices, concerns, and barriers to genetic testing and counseling was administered to the International Parkinson and Movement Disorders Society membership.RESULTS: Common hurdles across sites included cost and access to genetic testing, and counseling, as well as education on genetic counseling. Region-dependent differences in access to and availability of testing and counseling were most notable in Africa. High-income countries also demonstrated heterogeneity, with European nations more likely to have genetic testing covered through insurance than Pan-American and Asian countries.CONCLUSIONS: This survey highlights not only diversity of barriers in different regions but also the shared and highly actionable needs for improved education and access to genetic counseling and testing for PD worldwide. © 2023 International Parkinson and Movement Disorder Society.
  •  
3.
  • Winkler, TW, et al. (författare)
  • Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals
  • 2022
  • Ingår i: Communications biology. - : Springer Science and Business Media LLC. - 2399-3642. ; 5:1, s. 580-
  • Tidskriftsartikel (refereegranskat)abstract
    • Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (nDM = 178,691, nnoDM = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.
  •  
4.
  • Biasiotto, Roberta, et al. (författare)
  • Public Preferences for Digital Health Data Sharing : Discrete Choice Experiment Study in 12 European Countries.
  • 2023
  • Ingår i: Journal of Medical Internet Research. - : JMIR Publications. - 1438-8871. ; 25
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: With new technologies, health data can be collected in a variety of different clinical, research, and public health contexts, and then can be used for a range of new purposes. Establishing the public's views about digital health data sharing is essential for policy makers to develop effective harmonization initiatives for digital health data governance at the European level.OBJECTIVE: This study investigated public preferences for digital health data sharing.METHODS: A discrete choice experiment survey was administered to a sample of European residents in 12 European countries (Austria, Denmark, France, Germany, Iceland, Ireland, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom) from August 2020 to August 2021. Respondents answered whether hypothetical situations of data sharing were acceptable for them. Each hypothetical scenario was defined by 5 attributes ("data collector," "data user," "reason for data use," "information on data sharing and consent," and "availability of review process"), which had 3 to 4 attribute levels each. A latent class model was run across the whole data set and separately for different European regions (Northern, Central, and Southern Europe). Attribute relative importance was calculated for each latent class's pooled and regional data sets.RESULTS: A total of 5015 completed surveys were analyzed. In general, the most important attribute for respondents was the availability of information and consent during health data sharing. In the latent class model, 4 classes of preference patterns were identified. While respondents in 2 classes strongly expressed their preferences for data sharing with opposing positions, respondents in the other 2 classes preferred not to share their data, but attribute levels of the situation could have had an impact on their preferences. Respondents generally found the following to be the most acceptable: a national authority or academic research project as the data user; being informed and asked to consent; and a review process for data transfer and use, or transfer only. On the other hand, collection of their data by a technological company and data use for commercial communication were the least acceptable. There was preference heterogeneity across Europe and within European regions.CONCLUSIONS: This study showed the importance of transparency in data use and oversight of health-related data sharing for European respondents. Regional and intraregional preference heterogeneity for "data collector," "data user," "reason," "type of consent," and "review" calls for governance solutions that would grant data subjects the ability to control their digital health data being shared within different contexts. These results suggest that the use of data without consent will demand weighty and exceptional reasons. An interactive and dynamic informed consent model combined with oversight mechanisms may be a solution for policy initiatives aiming to harmonize health data use across Europe.
  •  
5.
  • Biasiotto, Roberta, et al. (författare)
  • The dynamic consent of the Cooperative Health Research in South Tyrol (CHRIS) study : broad aim within specific oversight and communication
  • 2021
  • Ingår i: BIOLAW JOURNAL-RIVISTA DI BIODIRITTO. - : UNIV TRENTO, FAC LAW. - 2284-4503. ; :1, s. 277-287
  • Tidskriftsartikel (refereegranskat)abstract
    • In biobanking and genomics research, data and samples are stored for long time and used in further studies, which may not be sufficiently specified or foreseen at the time of the initial consent. The dynamic consent of the CHRIS study integrates broad research aims, specific oversight and governance mechanisms, and continuous communication with participants, and allows nuanced choices to be changed over time. With this paper, we describe the CHRIS dynamic consent, and illustrate, by discussing data sharing and ongoing consent in the CHRIS study, how dynamic consent can actualize an informed consent model that is suitable for biobanking and genomic research.
  •  
6.
  •  
7.
  • Borry, Pascal, et al. (författare)
  • The challenges of the expanded availability of genomic information : an agenda-setting paper.
  • 2018
  • Ingår i: Journal of Community Genetics. - : Springer Science and Business Media LLC. - 1868-310X .- 1868-6001. ; 9:2, s. 103-116
  • Tidskriftsartikel (refereegranskat)abstract
    • Rapid advances in microarray and sequencing technologies are making genotyping and genome sequencing more affordable and readily available. There is an expectation that genomic sequencing technologies improve personalized diagnosis and personalized drug therapy. Concurrently, provision of direct-to-consumer genetic testing by commercial providers has enabled individuals' direct access to their genomic data. The expanded availability of genomic data is perceived as influencing the relationship between the various parties involved including healthcare professionals, researchers, patients, individuals, families, industry, and government. This results in a need to revisit their roles and responsibilities. In a 1-day agenda-setting meeting organized by the COST Action IS1303 "Citizen's Health through public-private Initiatives: Public health, Market and Ethical perspectives," participants discussed the main challenges associated with the expanded availability of genomic information, with a specific focus on public-private partnerships, and provided an outline from which to discuss in detail the identified challenges. This paper summarizes the points raised at this meeting in five main parts and highlights the key cross-cutting themes. In light of the increasing availability of genomic information, it is expected that this paper will provide timely direction for future research and policy making in this area.
  •  
8.
  • Cook, Lola, et al. (författare)
  • The commercial genetic testing landscape for Parkinson's disease
  • 2021
  • Ingår i: Parkinsonism & Related Disorders. - : Elsevier. - 1353-8020 .- 1873-5126. ; 92, s. 107-111
  • Tidskriftsartikel (refereegranskat)abstract
    • IntroductionThere have been no specific guidelines regarding which genes should be tested in the clinical setting for Parkinson's disease (PD) or parkinsonism. We evaluated the types of clinical genetic testing offered for PD as the first step of our gene curation.MethodsThe National Institutes of Health (NIH) Genetic Testing Registry (GTR) was queried on 12/7/2020 to identify current commercial PD genetic test offerings by clinical laboratories, internationally.ResultsWe identified 502 unique clinical genetic tests for PD, from 28 Clinical Laboratory Improvement Amendments (CLIA)-approved clinical laboratories. These included 11 diagnostic PD panels. The panels were notable for their differences in size, ranging from 5 to 62 genes. Five genes for variant query were included in all panels (SNCA, PRKN, PINK-1, PARK7 (DJ1), and LRRK2). Notably, the addition of the VPS35 and GBA genes was variable. Panel size differences stemmed from inclusion of genes linked to atypical parkinsonism and dystonia disorders, and genes in which the link to PD causation is controversial.ConclusionThere is an urgent need for expert opinion regarding which genes should be included in a commercial laboratory multi-gene panel for PD.
  •  
9.
  • Corradetti, Claudio, et al. (författare)
  • Patientcentricity
  • 2012
  • Ingår i: Studies in Ethics, Law, and Technology. - 1941-6008. ; 6:1, s. 1-2
  • Tidskriftsartikel (refereegranskat)
  •  
10.
  • Emmert, David B., et al. (författare)
  • Genetic and Metabolic Determinants of Atrial Fibrillation in a General Population Sample : The CHRIS Study
  • 2021
  • Ingår i: Biomolecules. - : MDPI. - 2218-273X. ; 11:11
  • Tidskriftsartikel (refereegranskat)abstract
    • Atrial fibrillation (AF) is a supraventricular arrhythmia deriving from uncoordinated electrical activation with considerable associated morbidity and mortality. To expand the limited understanding of AF biological mechanisms, we performed two screenings, investigating the genetic and metabolic determinants of AF in the Cooperative Health Research in South Tyrol study. We found 110 AF cases out of 10,509 general population individuals. A genome-wide association scan (GWAS) identified two novel loci (p-value < 5 x 10(-8)) around SNPs rs745582874, next to gene PBX1, and rs768476991, within gene PCCA, with genotype calling confirmed by Sanger sequencing. Risk alleles at both SNPs were enriched in a family detected through familial aggregation analysis of the phenotype, and both rare alleles co-segregated with AF. The metabolic screening of 175 metabolites, in a subset of individuals, revealed a 41% lower concentration of lysophosphatidylcholine lysoPC a C20:3 in AF cases compared to controls (p-adj = 0.005). The genetic findings, combined with previous evidence, indicate that the two identified GWAS loci may be considered novel genetic rare determinants for AF. Considering additionally the association of lysoPC a C20:3 with AF by metabolic screening, our results demonstrate the valuable contribution of the combined genomic and metabolomic approach in studying AF in large-scale population studies.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 55
Typ av publikation
tidskriftsartikel (46)
forskningsöversikt (8)
bok (1)
Typ av innehåll
refereegranskat (51)
övrigt vetenskapligt/konstnärligt (4)
Författare/redaktör
Mascalzoni, Deborah, ... (55)
Pramstaller, Peter P ... (11)
Pattaro, Cristian (7)
Biasiotto, Roberta (7)
Bentzen, Heidi Beate (7)
De Grandi, Alessandr ... (7)
visa fler...
Romano, Virginia (6)
Staunton, Ciara (6)
Klein, Christine (6)
Hicks, Andrew A. (5)
Taruscio, Domenica (5)
Fuchsberger, Christi ... (5)
Melotti, Roberto (5)
Foco, Luisa (5)
Kaye, Jane (4)
Veldwijk, Jorien (4)
Gainotti, Sabina (4)
Mendes, Álvaro (4)
Gögele, Martin (4)
Rossini, Alessandra (4)
Houeland, Gry (4)
Milne, Richard (4)
Middleton, Anna (3)
Shah, Nisha (3)
Ancillotti, Mirko, 1 ... (3)
Wjst, Matthias (3)
Wang, Nan (3)
Roberts, Jonathan (3)
Cong, Yali (3)
Patch, Christine (3)
Viberg Johansson, Je ... (3)
Tschigg, Katharina (3)
Prainsack, Barbara (3)
Howard, Heidi Carmen (3)
Smith, James (3)
Stefansdottir, Vigdi ... (3)
Cook, Lola (3)
Schulze, Jeanine (3)
Verbrugge, Jennifer (3)
Saunders-Pullman, Ra ... (3)
Alcalay, Roy N. (3)
Weichenberger, Chris ... (3)
Fernow, Josepine (3)
Bros-Facer, Virginie (3)
Roos, Marco (3)
Brüggemann, Norbert (3)
Pramstaller, Peter (3)
Tomasi, Marta (3)
Borsche, Max (3)
Kösters, Maria (3)
visa färre...
Lärosäte
Uppsala universitet (55)
Lunds universitet (6)
Karolinska Institutet (4)
Chalmers tekniska högskola (1)
Högskolan Dalarna (1)
Språk
Engelska (55)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (47)
Samhällsvetenskap (5)
Naturvetenskap (3)
Humaniora (3)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy